Épron Quievy & Associé advised Paltech SAS within it’s second fundraising
After a first fundraising in 2021, Paltech SAS closed in October 2023 a new round of more than one million euros fully subscribed by private investors.
Founded by doctors Réginald Allouche and Charles-Henri Malbert in 2021, Paltech SAS is an innovative company dedicated to the research for a curative treatment for type 2 diabetes.
Type 2 diabetes is a developing disease that affects more than 800 million people worldwide. The complications induced by this disease both in medium and long terms are strongly disabling. Type 2 diabetes is notably the main cause in non-traumatic amputations, blindness, kidney failure and neuropathy. Most treatments currently available are palliative and allow individuals to live with the disease without curing it. Paltech is developing a medical device that under certain conditions might cure people with type 2 diabetes. The first experiments made it possible to validate the proof of concept. Clinical trials with human beings are planned to start in 2025.
Paltech SAS is assisted by Épron Quievy & Associés on a day-to-day basis with Étienne Épron, partner and Cassandra Gimbert, associate.
More info on Paltech http://www.paltech.fr
Latest news
September 9, 2025
EQA Avocats Forms Strategic Alliance with Belgravia Law
We are pleased to announce the formation of a strategic partnership between EQA AVOCATS and BELGRAVIA LAW, an independent London-based law firm. BELGRAVIA LAW is recognized not only for its strategic approach and responsiveness but also for its expertise in cross-border litigation, international arbitration, and M&A. This partnership spans the jurisdictions of Paris, London, and… Continue reading EQA Avocats Forms Strategic Alliance with Belgravia Law
July 22, 2025
On 18 July 2025, the European Union took a significant new step in its sanctions strategy by adopting an expanded package targeting Russia and Belarus
This 18th sanctions package is notable in both scope and legal sophistication, reflecting a clear political intent to close loopholes, target logistical support networks, and tighten anti-circumvention measures. Several legal instruments have substantially broadened the range of economic, commercial, and financial prohibitions while introducing innovative legal safeguards—particularly against abusive legal claims based on investment treaties.… Continue reading On 18 July 2025, the European Union took a significant new step in its sanctions strategy by adopting an expanded package targeting Russia and Belarus
July 21, 2025
ACPR v. Banque Delubac: Circumvention Risk Under Scrutiny
1. Context On 19 June 2025, the Sanctions Committee of the French Prudential Supervision and Resolution Authority (ACPR) issued a decision against Banque Delubac & Cie, delivering a formal reprimand and imposing a financial penalty of €600,000 for multiple breaches of its anti-money laundering and counter-terrorism financing (AML/CFT) obligations. The decision, which is notably detailed,… Continue reading ACPR v. Banque Delubac: Circumvention Risk Under Scrutiny
July 21, 2025
Increase in Customs Duties on Agricultural Products and Fertilisers from Russia and Belarus
The European Union is adjusting its customs duties on Russian and Belarusian imports, citing the need to safeguard its food security and internal market. On 17 June 2025, the European Parliament and the Council of the European Union adopted Regulation (EU) 2025/1227, which modifies the applicable customs duties on certain products originating in or exported… Continue reading Increase in Customs Duties on Agricultural Products and Fertilisers from Russia and Belarus